Don't worry Sorepocket. FDA has no serious concerns. We will...

Don't worry Sorepocket. FDA has no serious concerns. We will meet with OTAT this quarter regarding potency and expecting a positive response then we will get our MOAT.

This will most likely lead to a fast approval time with Remestemcel for aGVHD full approval (ODAC still in favour) without any further trials necessary. Then we will have it approved in both Japan and the US which is 8 times bigger market (more revenues).

The signed Novartis collaboration agreement will most likely be finalised after positive OTAT meeting and MSB and Novartis will fast-track the last trial for COVID-19 ARDS, and soon we will be in the ICU's treating patients with COVID ARDS in combination with Dexa (very likely given our synergy with Dexa). And we know COVID isn't going anywhere in a hurry. What a huge revenue stream and goodwill worldwide. MSB will make a name for themselves (in combination with Dexa) being the only product to save lives when all other treatments have failed (and we know MSB does the heavy lifting).

And we will free up ICU beds (which will more that compensate for cost of product). Especially considering the money US is throwing at Monoclonals with some patients still progressing to ICUs. Win win. Lives saved. We make good money.

Looking forward to a very very very strong share price bounce with this fabulous upcoming news. Just be a little patient Sorepocket. We will get there very soon.